Logo image of ARGX.BR

ARGENX SE (ARGX.BR) Stock Fundamental Analysis

EBR:ARGX - Euronext Brussels - NL0010832176 - Common Stock - Currency: EUR

472.8  0 (0%)

Fundamental Rating

5

ARGX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. While ARGX seems to be doing ok healthwise, there are quite some concerns on its profitability. ARGX is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ARGX was profitable.
ARGX had a negative operating cash flow in the past year.
In the past 5 years ARGX reported 4 times negative net income.
In the past 5 years ARGX always reported negative operating cash flow.
ARGX.BR Yearly Net Income VS EBIT VS OCF VS FCFARGX.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

The Return On Assets of ARGX (13.42%) is better than 91.78% of its industry peers.
With an excellent Return On Equity value of 15.14%, ARGX belongs to the best of the industry, outperforming 83.56% of the companies in the same industry.
Industry RankSector Rank
ROA 13.42%
ROE 15.14%
ROIC N/A
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ARGX.BR Yearly ROA, ROE, ROICARGX.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30 -40

1.3 Margins

The Profit Margin of ARGX (38.01%) is better than 94.52% of its industry peers.
Looking at the Gross Margin, with a value of 89.65%, ARGX belongs to the top of the industry, outperforming 89.04% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 38.01%
GM 89.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARGX.BR Yearly Profit, Operating, Gross MarginsARGX.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARGX has more shares outstanding than it did 1 year ago.
ARGX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ARGX is higher compared to a year ago.
ARGX.BR Yearly Shares OutstandingARGX.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ARGX.BR Yearly Total Debt VS Total AssetsARGX.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

ARGX has an Altman-Z score of 29.48. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ARGX (29.48) is better than 98.63% of its industry peers.
ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ARGX has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. ARGX outperforms 84.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 29.48
ROIC/WACCN/A
WACC7.57%
ARGX.BR Yearly LT Debt VS Equity VS FCFARGX.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

ARGX has a Current Ratio of 7.29. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.29, ARGX belongs to the top of the industry, outperforming 90.41% of the companies in the same industry.
A Quick Ratio of 6.68 indicates that ARGX has no problem at all paying its short term obligations.
ARGX has a better Quick ratio (6.68) than 89.04% of its industry peers.
Industry RankSector Rank
Current Ratio 7.29
Quick Ratio 6.68
ARGX.BR Yearly Current Assets VS Current LiabilitesARGX.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

8

3. Growth

3.1 Past

ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 194.52%, which is quite impressive.
ARGX shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.82%.
ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.61% yearly.
EPS 1Y (TTM)194.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%348.08%
Revenue 1Y (TTM)31.82%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.72%

3.2 Future

ARGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.33% yearly.
Based on estimates for the next years, ARGX will show a very strong growth in Revenue. The Revenue will grow by 30.27% on average per year.
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y103.33%
Revenue Next Year64.81%
Revenue Next 2Y47.5%
Revenue Next 3Y39.17%
Revenue Next 5Y30.27%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARGX.BR Yearly Revenue VS EstimatesARGX.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ARGX.BR Yearly EPS VS EstimatesARGX.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 40 60 80

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 102.34, the valuation of ARGX can be described as expensive.
76.71% of the companies in the same industry are more expensive than ARGX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.34, ARGX is valued quite expensively.
With a Price/Forward Earnings ratio of 26.92, ARGX can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ARGX indicates a rather cheap valuation: ARGX is cheaper than 80.82% of the companies listed in the same industry.
ARGX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.19.
Industry RankSector Rank
PE 102.34
Fwd PE 26.92
ARGX.BR Price Earnings VS Forward Price EarningsARGX.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

72.60% of the companies in the same industry are more expensive than ARGX, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 25950.74
ARGX.BR Per share dataARGX.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 155.24% in the coming years.
PEG (NY)0.18
PEG (5Y)N/A
EPS Next 2Y242.7%
EPS Next 3Y155.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARGENX SE

EBR:ARGX (6/18/2025, 7:00:00 PM)

472.8

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners39.98%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap28.87B
Analysts84.62
Price Target686.38 (45.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7909.56%
Min EPS beat(2)-38.07%
Max EPS beat(2)15857.2%
EPS beat(4)2
Avg EPS beat(4)3984.41%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)2003.12%
EPS beat(12)8
Avg EPS beat(12)1344.81%
EPS beat(16)12
Avg EPS beat(16)1027.8%
Revenue beat(2)2
Avg Revenue beat(2)6.37%
Min Revenue beat(2)5.75%
Max Revenue beat(2)6.99%
Revenue beat(4)3
Avg Revenue beat(4)5.41%
Min Revenue beat(4)-0.25%
Max Revenue beat(4)9.17%
Revenue beat(8)7
Avg Revenue beat(8)7.53%
Revenue beat(12)11
Avg Revenue beat(12)27.61%
Revenue beat(16)14
Avg Revenue beat(16)43.67%
PT rev (1m)-1.81%
PT rev (3m)4.31%
EPS NQ rev (1m)2.35%
EPS NQ rev (3m)29.35%
EPS NY rev (1m)0%
EPS NY rev (3m)10.25%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)8.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.4%
Valuation
Industry RankSector Rank
PE 102.34
Fwd PE 26.92
P/S 15.24
P/FCF N/A
P/OCF N/A
P/B 6.07
P/tB 6.28
EV/EBITDA 25950.74
EPS(TTM)4.62
EY0.98%
EPS(NY)17.56
Fwd EY3.71%
FCF(TTM)-2.14
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS31.01
BVpS77.84
TBVpS75.27
PEG (NY)0.18
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.42%
ROE 15.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 38.01%
GM 89.65%
FCFM N/A
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 29.94
Cap/Depr 389.69%
Cap/Sales 3.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.29
Quick Ratio 6.68
Altman-Z 29.48
F-Score2
WACC7.57%
ROIC/WACCN/A
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)194.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%348.08%
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y103.33%
Revenue 1Y (TTM)31.82%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.72%
Revenue Next Year64.81%
Revenue Next 2Y47.5%
Revenue Next 3Y39.17%
Revenue Next 5Y30.27%
EBIT growth 1Y97.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1034.03%
EBIT Next 3Y192.38%
EBIT Next 5Y122%
FCF growth 1Y67.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.31%
OCF growth 3YN/A
OCF growth 5YN/A